2小时糖耐量试验的临床意义66课件.ppt

1、2小时糖耐量试验的临床意义小时糖耐量试验的临床意义 Finnish Academy Research Fellow芬兰赫尔辛基大学及芬兰赫尔辛基大学及 国立公共卫生研究院国立公共卫生研究院北大糖尿病论坛北大糖尿病论坛2007年年 5 月月12日，日，北京北京乔青乔青 MD,Ph.D 糖尿病诊断试验糖尿病诊断试验:历史回顾历史回顾糖尿病糖尿病症状症状尿糖尿糖空腹血糖空腹血糖糖耐量糖耐量(1913年年)Jacobsen A.Biochem Z 51:443,1913Normal Glucose Homeostasis Daytime Profile(N=12,health;Mean+95%CI)O

2、wens D,Zinman B&Bolli G:Lancet 358,739,2001Meal Times80400Insulin(mU/L)08.0013.0016.00 19.00 hGlucose(mmol/L)8426Bimodal distribution of glucoseand prevalence of retinopathy and proteinuria in Pima Indians Knowler WC etc.Diabetes Metab Rev 6:1-27,1990Copyright 1994 BMJ Publishing Group Ltd.McCane,D

3、R et al.BMJ 1994;308:1323-85 year cumulative incidence(top)and prevalence(bottom)of retinopathy in relation to tenths of 2hPG,FPG,and HBa1c 现用诊断标准现用诊断标准 NDDG1979:FPG=7.8 mmol/l and 75g OGTT at,1,1,2 hours WHO 1980:adopted the NDDG criteria,2h glucose=11.1 mmol/l after 75g load as“金标准金标准”WHO 1985:sli

4、ghtly modified the WHO 1980 criteria ADA 1997:FPG 7.8 mmol/l to 7.0 mmol/l，Not use OGTT WHO 1999:adopted the FPG 7.0 mmol/l,retained the 2h OGTT WHO/IDF 2006:no changes except for some terms 什么是糖耐量异常什么是糖耐量异常?1.均值均值+2标准差标准差2.血糖双峰分布血糖双峰分布,小血管病变小血管病变3.大血管病变大血管病变:心脑血管及外周血管病变心脑血管及外周血管病变 Dysglycemia Normo

5、glycemia in Acute and Stable CV Disease Consecutive pts:2107 in-pts;2854 out-pt elective CV consults in Europe(71%men;mean age 66)OGTT/old DM in 1587(75%)acute&1857(66%)elective pts before discharge or within 2 mo.NGTIFGIGTKnown DMNew DM29%35%22%22%31%30%15%10%3%3%020406080100%AcuteElectiveThe DECOD

6、E Study(http:/www.ktl.fi/decode/index.html)Diabetes Epidemiology:Collaborative analysis Of Diagnostic criteria in Europe Classification of individuals-the DECODE StudyDiscrepancy of FPG and 2hPG criteria in the DECODA study Diabetologia 2000;43:1470-1475051015202530Both2hPG=11.1FPG=7.0 30-39 40-49 5

7、0-59 60-69 70-79 80-89Prevalence(%)of newly diagnosed DM in DECODE populationsThe DECODE group,Diabetes Care 2003;26:61-69.051015202530354045IFG&IGTIGTIFG 30-39 40-49 50-59 60-69 70-79 80-89 Prevalence(%)of IGT but not IFG increases with age in DECODE populationThe DECODE group,Diabetes Care 2003;26

8、:61-69.Hazards ratio for all-cause mortality in subjects without prior history of diabetes Adj.for age,cohorts,sex,chol,BMI,SBP,smoking 2-hour plasma glucose(mmol/l)7.06.16.96.1 11.17.811.07.8Fasting plasma glucose(mmol/l)2.52.01.51.00.50.0Hazard ratioAdapted from DECODE Study Group,Lancet 1999;354:

9、6176211.000.580.520.560.590.820.470.500.540.660.840.920.00.20.40.60.81.01.2=11.10Known DM=7.006.10-6.995.75-6.094.75-5.7413.08.54.0Fasting plasma glucose(mmol/l)FrequencyHazard ratioDECODE,Diabetes Care 26:688-696Hazard ratio for mortality by FPG categories,the DECODA StudyFPG(mmol/l)6.1(n=5547)6.1-

10、6.9(n=462)7.0(n=297)P for trendCVDModel 1Model 2111.4(0.9-2.1)1.1(0.7-1.7)2.0(1.3-3.1)0.9(0.5-1.5)0.0060.83All-causeModel 1Model 2111.2(0.9-1.6)0.9(0.7-1.3)1.8(1.3-2.5)0.9(0.6-1.3)0.0010.81Model 1:Adjusted for age,sex,cohort,BMI,sysBP,Chol and smokingModel 2:Additional adjustment for 2hPG DECODA Stu

11、dy Group,Diabetologia 2004;47:385-394Hazard ratio for mortality by 2hPG categories,the DECODA Study2hPG(mmol/l)7.8(n=4753)7.8-11.0(n=1106)11.1(n=447)P for trendCVDModel 1Model 2111.3(0.9-1.9)1.3(0.9-1.9)3.2(2.2-4.7)3.4(2.1-5.4)0.0010.001All-causeModel 1Model 2111.3(1.0-1.7)1.4(1.0-1.8)2.9(2.2-3.8)3.

12、0(2.2-4.2)0.0010.001Model 1:Adjusted for age,sex,cohort,BMI,sysBP,Chol and smokingModel 2:Additional adjustment for FPG DECODA Study Group,Diabetologia 2004;47:385-394Non-diabetic DiabeticFollow-upBaseline 2hPGNGTIGTNon-diabeticCHD incidence 5.39.716.1CVD mortality3.17.98.7All-cause mortality7.612.8

13、15.5Incidence density(no./per 1000 person-years)Qiao et al.Diabetes Care 2003;26:2910-2914Hazard ratio(95%CI)by glucose status at baseline and at follow-upFollow-upNon-diabeticDiabeticBaseline 2hPGNGTIGTNon-diabeticCHD incidence11.5(1.0-2.3)1.8(1.0-3.2)CVD mortality12.3(1.4-3.9)1.7(0.8-3.5)All-cause

14、 mortality11.7(1.1-2.4)1.5(0.9-2.5)Adjusted for age,sex,WHR,SBP,Chol,HDL and smokingQiao et al.Diabetes Care 2003;26:2910-2914Effect of intensive glycemic control on the risk for any type of macrovascular eventsC Stettler,Am Heart J 2006;152:27-38STOP-NIDDM Trial(1)Myocardial infarctionAnginaRevascu

15、larization procedureCardiovascular deathCerebrovascular event or strokePeripheral vascular diseaseAny cardiovascular event FavoursAcarboseFavoursPlaceboChiasson JL JAMA 2003;23:290:486-94The main changes from baseline to 3 years:AcarbosePlaceboSTOP-NIDDM Trial(3)Body Weight(kg)-1.15 0.26BMI(kg/m2)-0

16、.60 -0.12Waist(cm)-0.62 0.17SysBP(mmHg)-0.97 -0.05DiasBP(mmHg)-2.8 -1.42hPG(mmol/L)-0.63 0.04Triglycerides(mmol/L)-0.18 -0.04All p 50 conventional pts-CV event 11 yrs post DCCT;17 yrs altogetherGHb Results:DCCT EndEDIC EndIntensive7.4(1.1)7.9(1.3)Conventional9.1(1.5)7.8(1.3)Intensive Insulin Rx&CVD:

17、T1 DM DCCT/EDIC NEJM 2005;353:2643Primary CV CompositeRRR=42%(9-63)RRR after adj.for updated GHb until end of DCCT(or CV event during DCCT):16%(-64 57)P=0.61Intensive Insulin Rx&CVD:T1 DM DCCT/EDIC NEJM 2005;353:2643MI,Stroke,CV DeathRRR=57%(12-79)Chronic G Lowering&CVD:IGT STOP NIDDM Analysis:Chias

18、son et al.JAMA 2003;290:486HR 0.51(0.28-0.95)(i.e.32/686 vs.15/682 MI,Angina,Revasc,CV Death,CHF,Stroke,or PVD)Copyright 1994 BMJ Publishing Group Ltd.McCane,D R et al.BMJ 1994;308:1323-8ROC curves for prevalence of retinopathy(top)and nephropathy(bottom)for 2hPG(-),FPG(.),and HbA1(-)concentrations1

19、-SpecificityRelative risk(95%CI)of mortality significantly increased in subjects with IGTHazards ratio for mortality in diabetic patients according to FPG Mortality FPG 7.0 mmol/l FPG 7.0 mmol/l adjusted for 2-hour glucose CVD 1.5(1.21.9)1.2(0.91.7)CHD 1.4(1.02.0)1.1(0.71.7)Stroke 1.9(1.23.2)1.7(0.9

20、3.1)All-cause 1.7(1.41.2)1.2(1.01.4)The DECODE group,Arch Intern Med 2001;161:397-404Adjusted for age,center,sex,cholesterol,BMI,BP,smoking Hazards ratio for mortality in diabetic patients according to 2-hour glucose Mortality 2-hour glucose 11.1 mmol/l 2-hour glucose 11.1 mmol/l adjusted for FPG CV

21、D 1.6(1.22.0)1.4(1.01.9)CHD 1.6(1.22.3)1.6(1.02.4)Stroke 1.7(1.03.0)1.3(0.72.5)All-cause 1.9(1.72.2)1.7(1.52.1)The DECODE group,Arch Intern Med 2001;161:397-404Adjusted for age,center,sex,cholesterol,BMI,BP,smoking nZq$t*x-A2D5G8KbNeQiTlXo#r%v(y+B3E6I9LcOgRjUmYp!t&w)z1C4F7JaMdPhSkWnZq$u*x-A2D5H8KbNf

22、QiTlXo#s%v(y0B3E6I9LdOgRjVmYp!t&w-z1C4G7JaMePhTkWnZr$u*x+A2E5H8KcNfQiUlXo#s%v)y0B3F6I9LdOgSjVmYq!t&w-z1D4G7JbMePhTkWoZr$u(x+A2E5H9KcNfRiUlXp#s&v)y0C3F6IaLdPgSjVnYq!t*w-A1D4G8JbMeQhTkWoZr%u(x+B2E5H9KcOfRiUmXp#s&v)z0C3F7IaLdPgSkVnYq$t*w-A1D5G8JbNeQhTlWo#r%u(y+B2E6H9LcOfRjUmXp!s&v)z0C4F7IaMdPgSkVnZq$t*

23、x-A1D5G8KbNeQiTlWo#r%v(y+B3E6H9LcOgRjUmYp!s&w)z1C4F7JaMdPhSkWnZq$u*x-A2D5G8KbNfQiTlXo#r%v(y0B3E6I9LcOgRjVmYp!t&w)z1C4G7JaMePhSkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F6I9LdOgSjVmYq!t&w-z1C4G7JbMePhTkWnZr$u(x+A2E5H8KcNfRiUlXp#s%v)y0C3F6IaLdOgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr%u(x+B2E5H9KcNfRiUmXp#s&v)y0C3F7IaL

24、dPgSjVnYq$t*w-A1D4G8JbNeQhTlWoZr%u(y+B2E6H9KcOfRjUmXp!s&v)z0C4F7IaMdPgSkVnZq$t*x-A1D5G8JbNeQiTlWo#r%u(y+B3E6H9LcOfRjUmYp!s&w)z0C4F7JaMdPhSkVnZq$u*x-A2D5G8KbNfQiTlXo#r%v(y0B3E6I9LcOgRjUmYp!t&w)z1C4F7JaMePhSkWnZq$u*x+A2D5H8KbNfQiUlXo#s%v(y0B3F6I9LdOgRjVmYq!t&w-z1C4G7JbMePhTkWnZr$u*x+A2E5H8KcNfQiUlXp#s

25、%v)y0B3F6IaLdOgSjVmYq!t*w-z1D4G7JbMeQhTkWoZr$u(x+B2E5H9KcNfRiUmXp#s&v)y0C3F7IaLdPgSjVnYq!t*w-A1D4G8JbMeQhTlWoZr%u(x+B2E6H9KcOfRiUmXp!s&v)z0C3F7IaMdPgSkVnYq$t*x-A1D5G8JbNeQiTlWo#r%u(y+B2E6H9LcOfRjUmXp!s&w)z0C4F7MeQhTlWoZr%u(x+B2E6H9KcOfRiUmXp!s&v)z0C3F7IaMdPgSkVnYq$t*x-A1D5G8JbNeQhTlWo#r%u(y+B2E6H9Lc

26、OfRjUmXp!s&w)z0C4F7IaMdPhSkVnZq$t*x-A2D5G8KbNeQiTlXo#r%v(y+B3E6I9LcOgRjUmYp!s&w)z1C4F7JaMdPhSkWnZq$u*x-A2D5H8KbNfQiTlXo#s%v(y0B3E6I9LdOgRjVmYp!t&w-z1C4G7JaMePhTkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F6I9LdOgSjVmYq!t&w-z1D4G7JbMePhTkWoZr$u(x+A2E5H9KcNfRiUlXp#s&v)y0C3F6IaLdPgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr%

27、u(x+B2E5H9KcOfRiUmXp#s&v)z0C3F7IaLdPgSkVnYq$t*w-A1D5G8JbNeQhTlWo#r%u(y+B2E6H9KcOfRjUmXp!s&v)z0C4F7IaMdPgSkVnZq$t*x-A1D5G8KbNeQiTlWo#r%v(y+B3E6H9LcOgRjUmYp!s&w)z1C4F7JaMdPhSkVnZq$u*x-A2D5G8KbNfQiTlXo#r%v(y0B3E6I9LcOgRjVmYp!t&w)z1C4G7JaMePhSkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F6I9LdOgRjVmYq!t&w-z1C4G7J

28、bMePhTkWnZr$u(x+A2E5H8KcNfRiUlXp#s%v)y0C3F6IaLdOgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr$u(x+B2E5H9KcNfRiUmXp#s&v)y0C3F7IaLdPgSjVnYq$t*w-A1D4G8JbNeQhTlWoZr%u(y+B2E6H9KcOfRjUmXp!s&v)z0C4F7IaMdPgSkVnYq$t*x-A1D5G8JbNeQiTlWo#r%u(y+B3E6H9LcOfRjUmYp!s&w)z0C4F7JaMdPhSkVnZq$u*2E6H9KcOfRiUmXp!s&v)z0C3F7IaMdPgSkVnYq$t*

29、x-A1D5G8JbNeQiTlWo#r%u(y+B3E6H9LcOfRjUmYp!s&w)z0C4F7JaMdPhSkVnZq$u*x-A2D5G8KbNeQiTlXo#r%v(y+B3E6I9LcOgRjUmYp!t&w)z1C4F7JaMePhSkWnZq$u*x+A2D5H8KbNfQiUlXo#s%v(y0B3F6I9LdOgRjVmYp!t&w-z1C4G7JaMePhTkWnZr$u*x+A2E5H8KcNfQiUlXp#s%v)y0B3F6IaLdOgSjVmYq!t*w-z1D4G7JbMeQhTkWoZr$u(x+A2E5H9KcNfRiUlXp#s&v)y0C3F6IaL

30、dPgSjVnYq!t*w-A1D4G8JbMeQhTlWoZr%u(x+B2E6H9KcOfRiUmXp!s&v)z0C3F7IaMdPgSkVnYq$t*w-A1D5G8JbNeQhTlWo#r%u(y+B2E6H9LcOfRjUmXp!s&w)z0C4F7IaMdPhSkVnZq$t*x-A2D5G8KbNeQiTlXo#r%v(y+B3E6H9LcOgRjUmYp!s&w)z1C4F7JaMdPhSkWnZq$u*x-A2D5H8KbNfQiTlXo#s%v(y0B3E6I9LdOgRjVmYp!t&w-z1C4G7JaMePhSkWnZr$u*x+A2D5H8KcNfQiUlXo#s

31、%v)y0B3F6I9LdOgSjVmYq!t&w-z1D4G7JbMePhTkWoZr$u(x+A2E5H9KcNfRiUp!t&w)z1C4G7JaMePhSkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F6I9LdOgSjVmYq!t&w-z1D4G7JbMePhTkWoZr$u(x+A2E5H8KcNfRiUlXp#s%v)y0C3F6IaLdOgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr%u(x+B2E5H9KcOfRiUmXp#s&v)z0C3F7IaLdPgSkVnYq$t*w-A1D4G8JbNeQhTlWoZr%u(y+B2E6H9Kc

32、OfRjUmXp!s&v)z0C4F7IaMdPgSkVnZq$t*x-A1D5G8KbNeQiTlWo#r%v(y+B3E6H9LcOfRjUmYp!s&w)z0C4F7JaMdPhSkVnZq$u*x-A2D5G8KbNfQiTlXo#r%v(y0B3E6I9LcOgRjVmYp!t&w)z1C4G7JaMePhSkWnZq$u*x+A2D5H8KbNfQiUlXo#s%v(y0B3F6I9LdOgRjVmYq!t&w-z1C4G7JbMePhTkWnZr$u(x+A2E5H8KcNfRiUlXp#s%v)y0C3F6IaLdOgSjVmYq!t*w-z1D4G7JbMeQhTkWoZr$

33、u(x+B2E5H9KcNfRiUmXp#s&v)y0C3F7IaLdPgSjZr$u(x+A2E5H8KcNfQiUlXp#s%v)y0B3F6IaLdOgSjVmYq!t*w-z1D4G7JbMeQhTkWoZr$u(x+B2E5H9KcNfRiUmXp#s&v)y0C3F7IaLdPgSjVnYq$t*w-A1D4G8JbMeQhTlWoZr%u(x+B2E6H9KcOfRiUmXp!s&v)z0C3F7IaMdPgSkVnYq$t*x-A1D5G8JbNeQiTlWo#r%u(y+B3E6H9LcOfRjUmXp!s&w)z0C4F7IaMdPhSkVnZq$t*x-A2D5G8KbN

34、eQiTlXo#r%v(y+B3E6I9LcOgRjUmYp!t&w)z1C4F7JaMePhSkWnZq$u*x+A2D5H8KbNfQiTlXo#s%v(y0B3E6I9LdOgRjVmYp!t&w-z1C4G7JaMePhTkWnZr$u*x+A2E5H8KcNfQiUlXp#s%v)y0B3F6IaLdOgSjVmYq!t&w-z1D4G7JbMePhTkWoZr$u(x+A2E5H9KcNfRiUlXp#s&v)y0C3F6IaLdPgSjVnYq!t*w-A1D4G8JbMeQhTlWoZr%u(x+B2E5H9KcOfRiUmXp#s&v)z0C3F7IaLdPgSkVnYq$+

35、A2E5H9KcNfRiUlXp#s&v)y0C3F6IaLdPgSjVnYq!t*w-A1D4G8JbMeQhTkWoZr%u(x+B2E5H9KcOfRiUmXp#s&v)z0C3F7IaLdPgSkVnYq$t*w-A1D5G8JbNeQhTlWo#r%u(y+B2E6H9LcOfRjUmXp!s&v)z0C4F7IaMdPgSkVnZq$t*x-A1D5G8KbNeQiTlWo#r%v(y+B3E6H9LcOgRjUmYp!s&w)z1C4F7JaMdPhSkWnZq$u*x-A2D5H8KbNfQiTlXo#r%v(y0B3E6I9LcOgRjVmYp!t&w)z1C4G7JaMeP

36、hSkWnZr$u*x+A2D5H8KcNfQiUlXo#s%v)y0B3F6I9LdOgSjVmYq!t&w-z1C4G7JbMePhTkWnZr$u(x+A2E5H8KcNfRiUlXp#s%v)y0C3F6IaLdOgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr%u(x+B2E5H9KcNfRiUmXp#s&v)y0C3F7IaLdPgSjVnYq$t*w-A1D4G8JbNeQhTlWoZr%u(y+B2E6HdOgSjVnYq!t*w-z1D4G8JbMeQhTkWoZr$u(x+B2E5H9KcNfRiUmXp#s&v)y0C3F7IaLdPgSjVnYq$t*w-A

37、1D4G8JbNeQhTlWoZr%u(y+B2E6H9KcOfRjUmXp!s&v)z0C3F7IaMdPgSkVnYq$t*x-A1D5G8JbNeQiTlWo#r%u(y+B3E6H9LcOfRjUmYp!s&w)z0C4F7JaMdPhSkVnZq$u*x-A2D5G8KbNfQiTlXo#r%v(y+B3E6I9LcOgRjUmYp!t&w)z1C4F7JaMePhSkWnZq$u*x+A2D5H8KbNfQiUlXo#s%v(y0B3F6I9LdOgRjVmYq!t&w-z1C4G7JaMePhTkWnZr$u*x+A2E5H8KcNfQiUlXp#s%v)y0B3F6IaLdOgSjVmYq!t*w-z1D4G7JbMeQhTkWoZr$u(x+BI9LdOgRjVmYp!t&w-z1C4G7JaMePhTkWnZr$u*x+A2E5H8KcNfQiUlXp#s%v)y0B3F6IaLdOgSjVmYq!